|| List of recent Proteins-related patents
| Novel brachiaria-urochloa endophytes|
The present invention relates to fungi of acremonium spp, wherein said fungi are purified or isolated from plants of the brachiaria-urochloa complex and wherein, when said fungi are inoculated into a plant, said plant has improved resistance to diseases and/or pests relative to an uninocualated control plant. The present invention also relates to plants inoculated with such fungi, products produced by the fungi and related genes, proteins and methods..
| Isolation of phosphoproteins, glycoproteins and fragments thereof|
The invention provides methods and apparatus for the selective isolation of phosphorylated and glycosylated proteins and their fragments. A lanthanide metal cation is used to precipitate proteins or protein fragments containing phospho groups and/or glyco groups.
| Production of polyols using distillers grains and proteins and lignin extracted from distillers grains|
Processes for the production of polyols from sources such as dried distillers grains plus solubles (ddgs) make use of a two-stage reaction scheme. In the first stage, the proteinaceous starting material is reacted with an aminating agent, such as diethanolamine (deoa), to generate amino-amides and amides.
| Modified polynucleotides for the production of proteins associated with blood and lymphatic disorders|
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmrna molecules.. .
| Methods of administering bone morphogenetic protein compositions|
The present invention relates to compositions of bone morphogenetic proteins, particularly solid and liquid formulations of such proteins comprising one or more stabilizing excipients. The invention further provides methods of producing the compositions, kits comprising the compositions and methods of using the compositions in the treatment of diseases of skeletal and non-skeletal tissues..
| Method for producing proteins in pichia pastoris that lack detectable cross binding activity to antibodies against host cell antigens|
Methods for producing proteins and glycoproteins in pichia pastoris that lack detectable cross binding activity to antibodies made against host cell antigens are described. In particular, methods are described wherein recombinant pichia pastoris strains that do not display a β-mannosyltransferase 2 activity with respect to an n-glycan or o-glycan and do not display at least one activity selected from a β-mannosyltransferase 1, 3, and 4 activity to produce recombinant proteins and glycoproteins.
| Molecular-based method of cancer diagnosis and prognosis|
A gene profiling signature for diagnosis and prognosis of cancer patients is disclosed herein. In one embodiment, the gene signature includes 32 or 79 cancer survival factor-associated genes.
| Compositions and methods to immunize against hepatitis c virus|
Compositions comprising viral antigens and antigenic peptides corresponding to or derived from hepatitis c virus (hcv) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (dcs) are described herein. Included herein are immunostimulatory compositions (hcv vaccines, hcv antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of hcv antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis c in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis c..
| Protein extraction|
A method for releasing the content of the periplasmic space of bacterial cells is provided, which comprises incubating the bacterial cells in a solution containing styrene maleic acid copolymer (sma). Also provided is a method of preparing a substantially pure sample of recombinant polypeptide.
| Method for preparing volatile fatty acids from the pre-treated extracts of marine biomass residue|
A method of preparing a volatile fatty acids (vfas) is provided. More particularly, the method includes chemically or biologically pretreating a residue of algae to obtain an extract of the algae residue, filtering the extract of the algae residue and anaerobically fermenting the filtrate.
| (r)- selective amination|
The present invention relates to a method for the enzymatic synthesis of enantiomerically enriched (r)-amines of general formula [c], from the corresponding ketones of general formula [a], by using novel transaminases. These novel transaminases are selected from two different groups: either from a group of some 20 proteins with sequences as specified herein, or from a group of proteins having transaminase activity and isolated from a microorganism selected from the group of organisms consisting of rahnella aquatilis, ochrobactrum anthropi, ochrobactrum tritici, sinorhizobium morelense, curtobacterium pusilllum, paecilomyces lilacinus, microbacterium ginsengisoli, microbacterium trichothecenolyticum, pseudomonas citronellolis, yersinia kristensenii, achromobacter spanius, achromobacter insolitus, mycobacterium fortuitum, mycobacterium frederiksbergense, mycobacterium sacrum, mycobacterium fluoranthenivorans, burkholderia sp., burkholderia tropica, cosmospora episphaeria, and fusarium oxysporum..
| Multiplex mrm assay for evaluation of cancer|
The current disclosure provides specific peptides, and derived ionization characteristics of the peptides from the estrogen receptor (er), progesterone receptor (pr), and/or antigen ki67 (ki67) proteins that are particularly advantageous for quantifying the er, pr, and/or ki67 proteins directly in biological samples that have been fixed in formalin by the method of selected reaction monitoring/multiple reaction monitoring (srm/mrm) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (ffpe) tissue/cells, ffpe tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
| Compositions and methods for capture of cellular targets of bioactive agents|
The present invention provides compositions and methods for capture and identification of the cellular targets of a bioactive agent. In particular, provided herein are bioactive agents tethered to capture ligand, cellular targets (optionally tagged with a reporter), capture proteins (optionally present as capture fusions), surfaces (e.g., displaying, capture ligands, capture proteins, or capture fusions), and methods of capturing and identifying the cellular targets of a bioactive agent therewith..
| Compositions and methods for recovery of nucleic acids or proteins from tissue samples fixed in cytology media|
The present invention provides compositions and methods for improving nucleic acid or protein recovery from fixed biological samples.. .
| Method for improving viscosity, solubility, and particle size of milk protein concentrates|
Disclosed is a method for decreasing viscosity, increasing solubility and decreasing particle size of milk proteins by admixing milk protein with at least one transglutaminase.. .
| New natural and synthetic compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
| Protein involved in detection of cancer metastasis and a treatment thereof|
Using phosphoproteomics, we profiled the phosphorylation levels of hundreds of proteins concurrently across an isogenic model of breast cancer metastasis. Among them is trpv4, a calcium channel that we found to be overexpressed in invasive breast tumors compared to ductal carcinoma in situ, a pre-neoplastic lesion and normal tissues.
| Monoclonal antibody|
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins.
| Compositions for regulating iron homeostasis and methods of using same|
The present disclosure relates to hemojuvelin-igg fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.. .
| Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof|
The present invention is based on the discovery of genetic polymorphisms that are associated with alzheimer's disease. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection..
| Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof|
Provided are soluble neutral active hyaluronidase glycoproteins (shasegp's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
| Methods for diagnosis, prognosis and methods of treatment|
The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population.
| Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity|
The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein.
|Method for isolating cell-type specific mrnas|
The invention provides methods for isolating cell-type specific mrnas by selectively isolating ribosomes or proteins that bind mrna in a cell type specific manner, and, thereby, the mrna hound to the ribosomes or proteins that bind mrna. Ribosomes, which are riboprotein complexes, bind mrna that is being actively translated in cells.
|Transgenic plants with enhanced agronomic traits|
This invention provides recombinant dna for expression of proteins that are useful for imparting enhanced agronomic trait(s) to transgenic crop plants. Also provided by this invention is transgenic seed for growing a transgenic plant having recombinant dna in its genome and exhibiting an enhance agronomic trait, i.e.
|Metamaterial optical elements self-assembled on protein scaffolds|
A genetically modified cowpea mosaic virus (cpmv) protein capsid serves as a scaffold for metal nanoparticles, preferably gold nanospheres, of 15 nm to 35 nm, creating plasmonic nanoclusters. The self-assembled nanoclusters gave rise to a 10-fold surface-averaged enhancement of the local electromagnetic field.
|Antibody drug conjugates (adc) that bind to 161p2f10b proteins|
Antibody drug conjugates (adc's) that bind to 161p2f10b protein are described herein. 161p2f10b exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i.
|B7-related nucleic acids and polypeptides useful for immunomodulation|
The present invention provides nucleic acids encoding b7-related factors that modulate the activation of immune or inflammatory response cells, such as t-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding b7-related polypeptides, including bsl1, bsl2, and bsl3.
|Dual specificity antibody fusions|
The present invention provides dual specificity antibody fusion proteins comprising an antibody fab or fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.. .
|Methods of targeted drug development|
Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as egfr, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration.
|Monomers capable of dimerizing in an aqueous solution, and methods of using same|
Described herein are monomers capable of forming a biologically useful multimer when in contact with one, two, three or more other monomers in an aqueous media. In one aspect, such monomers may be capable of binding to another monomer in an aqueous media (e.g.
|Agrocybe aegerita lectin aal-2, and encoding gene thereof, preparation method therefor and application thereof|
The isolated agrocybe aegerita lectin aal-2 is able to inhibit the growth of tumor cells by inducing apoptosis. In the animal study, the agrocybe aegerita lectin aal-2 has been showed to be capable for tumor therapy.
|Isolated nucleic acid molecules encoding variant activin receptor polypeptides|
The present invention provides variant activin iib soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin a, myostatin, or gdf-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins.
|Compositions and methods for treatment of metabolic disorders and diseases|
The invention relates to variants and fusions of fibroblast growth factor 19 (fgf19), variants and fusions of fibroblast growth factor 21 (fgf21), fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21), and variants or fusions of fibroblast growth factor 19 (fgf19) and/or fibroblast growth factor 21 (fgf21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.. .
|Hemipteran-and coleopteran active toxin proteins from bacillus thuringiensis|
A novel bacillus thuringiensis crystal protein exhibiting insect inhibitory activity is disclosed. Growth of lygus insects is significantly inhibited by providing the novel crystal protein in lygus insect diet.
The present invention relates to an n-glycosylated protein for treating and/or preventing bacterial pasteurellaceae infection in a mammal or bird, wherein the protein is a pasteurellaceae protein, a functional fragment or derivative thereof having at least one glycosylated n-x-s/t consensus sequence. In addition, the present invention is directed to corresponding pharmaceutical compositions for treating and/or protecting mammals or birds having or being prone to develop a bacterial pasteurellaceae infection.
|Nucleic acid sequences from diabrotica virgifera virgifera leconte and uses thereof|
Expressed sequence tags (ests) isolated from the western corn rootworm, diabrotica virgifera virgifera leconte, are disclosed. The invention encompasses nucleic acid molecules that encode d.
|Process for ultra-sensitive quantification of target analytes in complex biological systems|
Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment.
|Herbicide-resistant proteins, encoding genes, and uses thereof|
Some embodiments of the present invention can include herbicide-resistant proteins, coding genes, and uses thereof. Certain herbicide-resistant proteins can comprises: (a) a protein consisting of an amino acid sequence shown in seq id no: 2; or (b) a protein consisting of an amino acid sequence at least 90% identical to that set forth in seq id no: 2.
|Production of highly concentrated solutions of self-assembling proteins|
The present invention concerns stable aqueous protein dispersions comprising in an aqueous phase at least one self-assembling protein in dispersed form and also at least one specific dispersant for the self-assembling protein; processes for producing such stable aqueous dispersions; processes for electrospinning self-assembling proteins using such stable aqueous dispersions; processes for producing fibrous sheet bodies or fibers from such aqueous dispersions; the use of such aqueous dispersions for coating surfaces; the use of the materials produced by electrospinning in the manufacture of medical devices, hygiene articles and textiles; and also fibrous or fibrous sheet bodies produced by an electrospinning process of the present invention.. .
|Modulation of meiotic recombination|
The invention provides methods of modifying the level of expression or functional activity of factors such as enzymes or other catalytic proteins or structural proteins, alone or in concert, to modify the frequency of meiotic homologous recombination involving the exchange of genetic information between non-sister chromatids from homologous maternal and paternal chromosomes. The steps at which modulation may occur include: homologous chromosome pairing, double-strand break formation; resection; strand invasion; branch migration; and resolution.
|Methods of purification of native or mutant forms of diphtheria toxin|
The present invention relates to the use of hydroxyapatite chromatography and multimodal chromatography, for punfication of diphtheria toxin, or a mutant form thereof, from a mixture, for example, a host cell fermentation mixture containing impurities such as host cell proteins and dna. This invention further relates to the integration of such a method into a multi-step procedure with other fractionation methods for purification of diphtheria toxin suitable for in vitro and in vivo applications..
|Luminescent nanoparticle compositions|
A composition is disclosed which is capable of being used for detection, comprising a noble metal nanoparticle. The inventive compositions exhibit little interaction with serum proteins while exhibiting ph-dependent adsorption onto live cell membranes.
|Isolation and detection of cancer cells|
Provided are methods of using polycarbonate filters to isolate and detect cancer cells in a biological fluid, particularly biological fluids, such as urine, that contain very low concentrations of cancer cells. The characterization of the isolated cells for the presence or absence of cancer specific proteins is useful for cancer diagnosis and prognosis..
|Method for reducing sodium content in proteins|
A method for reducing sodium content in proteins including the steps of placing a protein having a sodium content in a solution having acid for a predetermined period of time and removing the protein from the solution.. .
|Protein free formula|
Wherein the indigestible carbohydrate is selected from a milk protein free source and the total composition is essentially free of intact proteins.. .
|Methods for cancer treatment using stem cells|
Various embodiments of the invention provide methods of treating cancer. Many embodiments provide methods of treating cancer using stem cells.
|Peptide carrier fusion proteins as allergy vaccines|
The present invention relates to a polypeptide comprising at least three peptide fragments consisting of 10 to 50 consecutive amino acid residues of at least one wild-type allergen fused to the n- and c-terminus of a surface polypeptide of a virus of the hepadnaviridae family or at least one fragment of said surface polypeptide.. .
|Functional influenza virus-like particles (vlps)|
The present invention discloses and claims virus like particles (vlps) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising vlps of the inventions.
|Markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chemotherapy|
The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment.
|Treatment of cutaneous wounds by inhibiting cold shock proteins|
Disclosed are methods of treating a subject suffering from a cutaneous wound comprising administering to the subject a cirp inhibitor.. .
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
|Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein|
Compositions comprising tl1a-ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a tnfrsf25 agonist and an interleukin (e.g., il-2) and/or an mtor inhibitor (e.g., rapamycin)..
|Fusion proteins for delivery of gdnf to the cns|
The invention provides compositions, methods, and kits for increasing transport of gdnf across the blood brain barrier while allowing its activity to remain substantially intact. The gdnf is transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems..
|Soluble proteins for use as therapeutics|
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
|Methods and compositions to detect the level of lysosomal exocytosis activity and methods of use|
Methods are provided for the prognosis, diagnosis and treatment of various pathological states, including cancer, chemotherapy resistance and dementia associated with alzheimer's disease. The methods provided herein are based on the discovery that various proteins with a high level of sialylation are shown herein to be associated with disease states, such as, cancer, chemotherapy resistance and dementia associated with alzheimer's disease.
|Method for enzymatic cross-linking of a protein|
A method for cross-linking albumin for use as a sealant or glue for a biological system, for example to induce hemostasis and/or prevent leakage of any other fluid from a biological tube or tissue, such as lymph for example. The cross-linked albumin may optionally and preferably be applied as part of a bandage for example.
|Treating cancer stem cells using targeted cargo proteins|
The disclosure provides targeted cargo proteins that are useful for targeting cancer stem cells, and methods of their use in treating cancer.. .
|Derivatives of recombinant proteins, homo-multimers of granulocyte colony-stimulating factor and method of preparation thereof|
The invention relates to derivatives of recombinant proteins, comprising homo-multimers of genetically fused recombinant biologically active protein monomer units, connected via selected peptide linker moiety; and the method of preparation thereof. Derivative of recombinant protein is preferably dimer of human granulocyte colony-stimulating factor, characterised by increased circulation time in vivo..
|Method for recycling metals|
A method for recycling metals is provided by using extracellular proteins excreted by a specific thermophilic bacteria strain, tepidimonas fonticaldi sp. Nov., in which the extracellular proteins show excellent metal-ion binding ability, being useful in recycling rare earth metal ions and precious metal ions from geothermal fluids, boiler solutions, industrial wastewater or hard water..